MX2021002181A - Inhibicion de la integrina alfa v beta 6. - Google Patents

Inhibicion de la integrina alfa v beta 6.

Info

Publication number
MX2021002181A
MX2021002181A MX2021002181A MX2021002181A MX2021002181A MX 2021002181 A MX2021002181 A MX 2021002181A MX 2021002181 A MX2021002181 A MX 2021002181A MX 2021002181 A MX2021002181 A MX 2021002181A MX 2021002181 A MX2021002181 A MX 2021002181A
Authority
MX
Mexico
Prior art keywords
integrin
compounds
assay
evaluate
inhibiting
Prior art date
Application number
MX2021002181A
Other languages
English (en)
Inventor
Blaise S Lippa
Bruce N Rogers
Aleksey I Gerasyuto
Cheng Zhong
Bryce A Harrison
James E Dowling
Matthew G Bursavich
Dawn M Troast
Kristopher N Hahn
Qi Qiao
fu-yang Lin
Brian Sosa
Andrea Bortolato
Mats A Svensson
Eugene Hickey
Kyle D Konze
Tyler Day
Byungchan Kim
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of MX2021002181A publication Critical patent/MX2021002181A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen inhibidores de molécula pequeña de la integrina avß6, y métodos para usarlos para tratar una serie de enfermedades y afecciones. Los solicitantes han descubierto nuevos compuestos inhibidores de la integrina avß6 y han evaluado la posesión, el rendimiento y la utilidad de ejemplos representativos de tales compuestos, tanto para la potencia bioquímica (por ejemplo, mediante el uso del ensayo del Ejemplo 35 para evaluar los ensayos de polarización de fluorescencia de compuestos para la unión de avß6) como las propiedades de permeabilidad in vitro (por ejemplo, mediante el uso del ensayo del Ejemplo 36 para evaluar la permeabilidad en MDCK).
MX2021002181A 2018-08-29 2019-08-29 Inhibicion de la integrina alfa v beta 6. MX2021002181A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724423P 2018-08-29 2018-08-29
US201962859457P 2019-06-10 2019-06-10
PCT/US2019/048782 WO2020047239A1 (en) 2018-08-29 2019-08-29 INHIBITING αV β6 INTEGRIN

Publications (1)

Publication Number Publication Date
MX2021002181A true MX2021002181A (es) 2021-07-15

Family

ID=67809398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002181A MX2021002181A (es) 2018-08-29 2019-08-29 Inhibicion de la integrina alfa v beta 6.

Country Status (22)

Country Link
US (4) US20200071322A1 (es)
EP (2) EP4086254A1 (es)
JP (1) JP2021535141A (es)
KR (1) KR20210065935A (es)
CN (1) CN112805001A (es)
AU (1) AU2019327475A1 (es)
BR (1) BR112021003859A2 (es)
CA (1) CA3109534A1 (es)
CL (1) CL2021000484A1 (es)
CO (1) CO2021002706A2 (es)
CR (1) CR20210109A (es)
DO (1) DOP2021000035A (es)
EC (1) ECSP21013620A (es)
IL (1) IL280782A (es)
MA (1) MA51066A (es)
MX (1) MX2021002181A (es)
PE (1) PE20211640A1 (es)
PH (1) PH12021550404A1 (es)
SG (1) SG11202101913PA (es)
TW (1) TW202035400A (es)
UY (1) UY38353A (es)
WO (1) WO2020047239A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
EP4159727A1 (en) 2017-02-28 2023-04-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
ES2972512T3 (es) 2018-03-07 2024-06-13 Pliant Therapeutics Inc Compuestos de aminoácido y métodos de uso
SG11202013027RA (en) 2018-06-27 2021-01-28 Pliant Therapeutics Inc Amino acid compounds with unbranched linkers and methods of use
PE20211640A1 (es) 2018-08-29 2021-08-24 Morphic Therapeutic Inc INHIBICION DE LA INTEGRINA xvß6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
EP3873884A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
JP7491996B2 (ja) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリンの阻害のための化合物
MX2023002854A (es) * 2020-09-11 2023-04-03 Arrowhead Pharmaceuticals Inc Plataformas de suministro al musculo esqueletico y metodos de uso.

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0612313A1 (en) 1991-11-14 1994-08-31 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
US20010034445A1 (en) 1995-12-29 2001-10-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
PL327626A1 (en) 1995-12-29 1998-12-21 Smithkline Beecham Corp Antagonists of vitronectin receptor
IL125034A0 (en) 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
CA2242877A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
NZ500927A (en) 1996-03-29 2004-11-26 Pfizer 6-Phenylpyridyl-2-amine derivatives
JP2002511052A (ja) 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
ES2194223T3 (es) 1996-10-30 2003-11-16 Merck & Co Inc Antagonistas de la integrina.
US5952341A (en) 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
WO1998046220A1 (en) 1997-04-14 1998-10-22 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
AU1523199A (en) 1997-11-26 1999-06-15 Du Pont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
PT1040111E (pt) 1997-12-17 2005-10-31 Merck & Co Inc Antagonistas do receptor da integrina
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
AU738452B2 (en) 1997-12-17 2001-09-20 Merck & Co., Inc. Integrin receptor antagonists
BR9813769A (pt) 1997-12-17 2000-10-10 Merck & Co Inc Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste.
CA2315370A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
CA2355874A1 (en) 1998-12-19 2000-06-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung .alpha.v.beta.6 integrin inhibitors
JP2002536370A (ja) 1999-02-03 2002-10-29 メルク エンド カムパニー インコーポレーテッド α−Ｖインテグリン受容体拮抗薬としてのベンゾアゼピン誘導体
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CA2373937A1 (en) 1999-06-02 2000-12-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
AU780364B2 (en) 2000-01-20 2005-03-17 Merck Sharp & Dohme Corp. Alpha V integrin receptor antagonists
JP2003520271A (ja) 2000-01-24 2003-07-02 メルク エンド カムパニー インコーポレーテッド αｖインテグリン受容体拮抗薬
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
CA2421652A1 (en) 2000-09-14 2002-03-21 Merck And Co., Inc. Alpha v integrin receptor antagonists
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2002022124A1 (en) 2000-09-18 2002-03-21 Merck & Co., Inc. Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
JP4615826B2 (ja) 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
JP2004528373A (ja) 2001-05-03 2004-09-16 メルク　エンド　カムパニー　インコーポレーテッド ベンズアゼピノンαＶインテグリン受容体拮抗物質
US20040043988A1 (en) 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
US20040077684A1 (en) 2002-08-16 2004-04-22 Bart De Corte Piperidinyl compounds that selectively bind integrins
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
EP2049490A1 (en) 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
AU2008266228A1 (en) 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
CA2705916C (en) 2007-11-16 2016-01-05 Ube Industries, Ltd. Benzazepinone compound
US20120289481A1 (en) 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
WO2014015054A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2015179823A2 (en) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
WO2016022851A1 (en) 2014-08-06 2016-02-11 Children's Medical Center Corporation Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
WO2016153054A1 (ja) 2015-03-25 2016-09-29 富士フイルム株式会社 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体
EP3288555A1 (en) 2015-04-30 2018-03-07 SciFluor Life Sciences, Inc. Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
AU2016381336A1 (en) 2015-12-30 2018-06-28 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
JP2019524702A (ja) 2016-07-05 2019-09-05 ザ ロックフェラー ユニバーシティー テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
TWI776821B (zh) 2016-11-01 2022-09-11 美商愛羅海德製藥公司 α-V β-6整合素配位子
WO2018085578A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin inhibitors in combination with an agent which interacts with a chemokine receptor
WO2018085552A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
LT3538528T (lt) 2016-11-08 2021-03-10 Bristol-Myers Squibb Company Pirolo amidai, kaip alfa v integrino inhibitoriai
MA46746A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
BR112019009129A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina
AU2017359027A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Indazole derivatives as αV integrin antagonists
PT3538525T (pt) 2016-11-08 2022-08-16 Bristol Myers Squibb Co Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina
EP3558303A4 (en) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. AMINO ACID COMPOUNDS AND METHOD FOR USE
WO2018132268A1 (en) 2016-12-29 2018-07-19 Saint Louis University Integrin antagonists
EP4159727A1 (en) 2017-02-28 2023-04-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
ES2972512T3 (es) 2018-03-07 2024-06-13 Pliant Therapeutics Inc Compuestos de aminoácido y métodos de uso
SG11202013027RA (en) 2018-06-27 2021-01-28 Pliant Therapeutics Inc Amino acid compounds with unbranched linkers and methods of use
US20210284638A1 (en) 2018-07-03 2021-09-16 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS
PE20211640A1 (es) 2018-08-29 2021-08-24 Morphic Therapeutic Inc INHIBICION DE LA INTEGRINA xvß6
EP3843727A4 (en) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS
WO2020047207A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AR116036A1 (es) 2018-08-29 2021-03-25 Morphic Therapeutic Inc DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案

Also Published As

Publication number Publication date
US20200354359A1 (en) 2020-11-12
WO2020047239A1 (en) 2020-03-05
US11021480B2 (en) 2021-06-01
US11739087B2 (en) 2023-08-29
US20200071322A1 (en) 2020-03-05
KR20210065935A (ko) 2021-06-04
CO2021002706A2 (es) 2021-05-20
BR112021003859A2 (pt) 2021-05-18
IL280782A (en) 2021-04-29
JP2021535141A (ja) 2021-12-16
EP3617206A1 (en) 2020-03-04
AU2019327475A1 (en) 2021-03-11
PE20211640A1 (es) 2021-08-24
DOP2021000035A (es) 2021-06-30
EP4086254A1 (en) 2022-11-09
US20200385384A1 (en) 2020-12-10
UY38353A (es) 2020-03-31
SG11202101913PA (en) 2021-03-30
CL2021000484A1 (es) 2021-09-03
CR20210109A (es) 2021-06-24
MA51066A (fr) 2020-10-14
ECSP21013620A (es) 2021-05-31
CN112805001A (zh) 2021-05-14
TW202035400A (zh) 2020-10-01
US20220073511A1 (en) 2022-03-10
CA3109534A1 (en) 2020-03-05
PH12021550404A1 (en) 2021-10-04

Similar Documents

Publication Publication Date Title
MX2021002181A (es) Inhibicion de la integrina alfa v beta 6.
WO2020047207A8 (en) Inhibitors of (alpha-v)(beta-6) integrin
UY29479A1 (es) Inhibidores de adn-pk
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
MX2010002783A (es) Proceso e intermediarios para la preparacion de inhibidores de integrasa.
AR054533A1 (es) Proceso y reactivo magnetico para la separacion de impurezas de los minerales
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
DE602006009789D1 (de) Acetylenderivate
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
CU23889B1 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antinflamatorios
ECSP099070A (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
EP2197455A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING INHIBITORS OF RETROVIRAL INFECTIONS
BRPI0803636A2 (pt) processo para a sìntese de ranelato de estrÈncio e seus hidratos
WO2008064304A3 (en) Compositions and methods for the identification of inhibitors of protein synthesis
BRPI0508471A8 (pt) compostos de hidróxi-6-fenilfenantidinas substituídas por difluoroetóxi, composição farmacêutica e uso para a produção dos mesmos
DK2005190T4 (da) Inhibering af GASC1
DE602006008751D1 (de) Synthese von proteaseinhibitorvorstufen
BRPI0406970A (pt) Modificação cristalina de um complexo de manganês
GT200600447A (es) Proceso para la síntesis de compuestos para la inhibición de selectina
TW200738731A (en) Substituted aminophenylsulfonamide compounds and derivatives as HIV protease inhibitor
ATE449863T1 (de) Verwendung von lepa zur verbesserung der genauigkeit der in-vitro-proteinsynthese
BRPI1009237A2 (pt) inibidores de ligação de proteína quinase.
CL2011000932A1 (es) Proceso para la preparacion de 9-diclorometilen-1,2,3,3-tetrahidro-1,4-metano-naftalen-5-ilamina; compuesto intermedio y proceso para preparar 6,6-diclorfulveno.